Nuvation Bio (NUVB) risk factors
Item 1A of every Nuvation Bio Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors106 risks22 new17 dropped19 reworded
Transitioned to a commercial-stage company following June 2025 FDA approval of IBTROZI for ROS1+ NSCLC. Faces risks regarding commercial adoption, distribution networks, and post-marketing study requirements.
Filed Mar 02, 2026 - FY2024 10-K risk factors101 risks
Nuvation Bio faces heavy dependence on unapproved clinical candidates like taletrectinib and safusidenib requiring substantial additional capital. Significant debt of up to $250.0 million from Sagard constrains operational flexibility and cash flow. Preclinical and clinical trial execution, regulatory hurdles, and intense biotechnology competition threaten future commercial success.
Filed Mar 06, 2025